Celsion Corp (CLSN.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|58||2014||Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer|
|55||2014||Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy|
|55||2014||Senior Vice President and Chief Medical Officer|
|64||2014||Executive Chairman of the Board, President, Chief Executive Officer|
- BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol
- BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook
- BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy
- BRIEF-Celsion reports Q3 loss of $0.70/shr
- BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1